Your session is about to expire
← Back to Search
Aticaprant for Depression (VENTURA-LT Trial)
VENTURA-LT Trial Summary
This trial is testing a new drug to see if it's safe and effective when used with current antidepressants to treat people with major depressive disorder.
VENTURA-LT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVENTURA-LT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 163 Patients • NCT02218736VENTURA-LT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I've tried at least one antidepressant for my current depression episode without enough improvement.I completed a specific study without stopping or changing my depression medication early.I have not followed my antidepressant treatment as prescribed.I completed a previous study without stopping or changing my depression medication early.I am not hospitalized and will start treatment as an outpatient.I have been diagnosed with major depression without psychosis.I've tried at least one antidepressant for my current depression episode without enough improvement.I am not hospitalized and will start treatment as an outpatient.I've tried 1-3 antidepressants for my current depression episode without enough improvement.I completed a previous study without stopping or changing my depression medication early.I am not hospitalized and will start treatment as an outpatient.I have been diagnosed with major depression without psychosis.Participants should not take any medications or food supplements that may interact with the study drug.
- Group 1: Aticaprant 10 mg
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What therapeutic goal does this research hope to realize?
"The primary objective of this clinical trial, which will be evaluated over the course of 54 weeks, is to study the number of participants that experience sexual dysfunction as measured by the Arizona Sexual Experiences Scale (ASEX). Additionally, this trial will also measure secondary outcomes including the percentage of participants that experience remission of depressive symptoms over time, as well as changes in the Montgomery-asberg Depression Rating Scale (MADRS) total score and the Clinical Global Impression-Severity (CGI-S) total score over time."
Has the FDA sanctioned Aticaprant for public use?
"There is pre-existing clinical evidence suggesting that Aticaprant is safe for human use, which is why it was given a score of 3."
Are people of all ages being sought for this clinical trial?
"The age limit for participants in this study is 74 years old, provided they are also above 18 years old."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Typically responds via
Most responsive sites:
- North Texas Clinical Trials: < 24 hours
- R and H Clinical Research: < 24 hours
- NoesisPharma Research: < 24 hours
Average response time
- < 2 Days
Share this study with friends
Copy Link
Messenger